Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.9% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 561 shares of the biopharmaceutical company’s stock after acquiring an additional 36 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $313,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. ARK Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 169.8% in the first quarter. ARK Investment Management LLC now owns 1,218,970 shares of the biopharmaceutical company’s stock valued at $576,743,000 after purchasing an additional 767,152 shares during the period. JPMorgan Chase & Co. boosted its position in Regeneron Pharmaceuticals by 31.6% in the first quarter. JPMorgan Chase & Co. now owns 3,035,655 shares of the biopharmaceutical company’s stock valued at $1,436,290,000 after buying an additional 728,261 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Regeneron Pharmaceuticals by 351.5% in the 1st quarter. Acadian Asset Management LLC now owns 425,374 shares of the biopharmaceutical company’s stock worth $201,262,000 after buying an additional 331,154 shares during the period. Putnam Investments LLC raised its position in Regeneron Pharmaceuticals by 54.6% during the 1st quarter. Putnam Investments LLC now owns 655,652 shares of the biopharmaceutical company’s stock worth $310,215,000 after buying an additional 231,463 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in Regeneron Pharmaceuticals by 33.6% during the 1st quarter. Neuberger Berman Group LLC now owns 755,789 shares of the biopharmaceutical company’s stock worth $357,414,000 after buying an additional 190,230 shares during the last quarter. Institutional investors and hedge funds own 82.31% of the company’s stock.

In related news, insider George Yancopoulos sold 80,000 shares of the stock in a transaction that occurred on Monday, June 21st. The stock was sold at an average price of $538.90, for a total value of $43,112,000.00. Following the completion of the transaction, the insider now directly owns 987,483 shares in the company, valued at $532,154,588.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $564.50, for a total value of $56,450.00. Following the completion of the transaction, the director now directly owns 23,589 shares in the company, valued at approximately $13,315,990.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 389,040 shares of company stock valued at $240,594,454. 11.84% of the stock is owned by corporate insiders.

A number of analysts have recently weighed in on the stock. Benchmark increased their price objective on shares of Regeneron Pharmaceuticals from $636.00 to $727.00 and gave the stock a “buy” rating in a research note on Monday, August 23rd. Barclays increased their price target on Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Oppenheimer boosted their price objective on Regeneron Pharmaceuticals from $725.00 to $825.00 and gave the company an “outperform” rating in a report on Friday, August 6th. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $670.00 to $700.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Royal Bank of Canada boosted their price target on Regeneron Pharmaceuticals from $629.00 to $679.00 and gave the company a “sector perform” rating in a report on Friday, July 23rd. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Buy” and an average target price of $691.65.

NASDAQ REGN opened at $651.88 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.57 and a quick ratio of 3.04. The stock’s 50 day simple moving average is $625.48 and its 200-day simple moving average is $545.68. The company has a market cap of $69.72 billion, a PE ratio of 11.71, a price-to-earnings-growth ratio of 0.77 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 1-year low of $441.00 and a 1-year high of $686.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 5th. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $8.81 by $16.99. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $3.90 billion. Regeneron Pharmaceuticals had a net margin of 50.11% and a return on equity of 50.43%. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 51.91 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Further Reading: What is the Beige Book?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.